Lebwohl, M., Gooderham, M., Warren, R. B., Thaçi, D., Foley, P., Gottlieb, A. B., Hippeli, L., Kisa, R. M., Banerjee, S., & Griffiths, C. E. (2023). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial. SKIN The Journal of Cutaneous Medicine, 7(6), s239. https://doi.org/10.25251/skin.7.supp.239